BridgeBio Pharma, Inc. (BBIO) Revenue History
Annual and quarterly revenue from 2017 to present
BBIO Revenue Over Time (2017–2025)
BBIO Revenue Growth History
4 of 6 years with positive growth- FY2017 revenue growth
- N/A
- FY2018 revenue growth
- N/A
- FY2019 revenue growth
- N/A
- FY2020 revenue growth
- -79.7%
- FY2021 revenue growth
- +745.1%
- FY2022 revenue growth
- +11.4%
- FY2023 revenue growth
- -88.0%
- FY2024 revenue growth
- +2285.3%
- FY2025 revenue growth
- +126.3%
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $222.4M | +101.2% |
| Q1 2026 | $194.5M | +66.8% |
| Q4 2025 | $154.2M | +2521.2% |
| Q3 2025 | $120.7M | +4318.0% |
| Q2 2025 | $110.6M | +4999.9% |
| Q1 2025 | $116.6M | -44.8% |
| Q4 2024 | $5.9M | +237.1% |
| Q3 2024 | $2.7M | -33.2% |
Multi-year avg. share of annual revenue by fiscal quarter
Revenue Breakdown (FY 2025)
BBIO's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
BBIO Revenue Analysis (2017–2025)
Current Revenue & Growth
As of October 3, 2026, BridgeBio Pharma, Inc. (BBIO) generated trailing twelve-month (TTM) revenue of $691.8 million, reflecting explosive growth of +101.2% year-over-year. The most recent quarter (Q2 2026) recorded $222.4 million in revenue, up 14.4% sequentially.
Historical Growth Trajectory
BBIO's 5-year compound annual growth rate (CAGR) stands at +127.4%, indicating outstanding long-term growth trajectory. The 3-year CAGR of +86.3% is below the 5-year average, signalling a growth deceleration in recent years. BridgeBio Pharma, Inc.'s highest annual revenue of $502.1 million was recorded in 2025, an all-time high.
Revenue by Segment
BBIO's revenue is primarily driven by Product (72%), License and Service (26%), and Royalty (2%). With over half of revenue concentrated in Product, the company has a focused business model while developing other growth vectors.
Peer Comparison
Compared to Healthcare sector peers — including KYMR (+134.8% YoY), ARRY (+1.2% YoY), and RCUS (-55.3% YoY) — BBIO has outperformed the peer group in revenue growth. Compare BBIO vs KYMR →
BBIO Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| BBIOCurrent | $692M | +101.2% | +127.4% | -113.3% | |
 KYMR | $39M | +134.8% | +2.9% | -891.3% | |
 ARRY | $1.3B | +1.2% | +8.0% | 5.7% | |
 RCUS | $247M | -55.3% | +25.9% | -156.3% | |
 VRTX | $12.1B | +10.6% | +14.2% | 39.4% |
BBIO Historical Revenue Data (2017–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $502.1M | +126.3% | $473.8M | 94.4% | $-569,087,000 | -113.3% |
| 2024 | $221.9M | +2285.3% | $218.0M | 98.3% | $-592,973,000 | -267.2% |
| 2023 | $9.3M | -88.0% | $6.9M | 73.7% | $-607,370,000 | -6528.8% |
| 2022 | $77.6M | +11.4% | $74.2M | 95.6% | $-512,202,000 | -659.6% |
| 2021 | $69.7M | +745.1% | $66.6M | 95.5% | $-576,632,000 | -827.1% |
| 2020 | $8.2M | -79.7% | $8.2M | 100.0% | $-474,482,000 | -5752.0% |
| 2019 | $40.6M | - | $38.1M | 93.8% | $-266,240,000 | -656.4% |
| 2018 | $0 | - | $0 | - | $-183,660,000 | - |
| 2017 | $0 | - | $-260,000 | - | $-43,858,000 | - |
BBIO Chart Terminal
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
Live Breakouts Feed
High-probability breakout stocks crossing their pivot across 5 pattern engines.
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
9+ years return with dividends reinvested.
Peer Comparison
Compare growth, multiples, and margins vs sector.
BBIO — Frequently Asked Questions
Quick answers to the most common questions about buying BBIO stock.
Is BBIO's revenue growth accelerating or slowing?
BBIO revenue growth is accelerating. TTM revenue reached $692M, up +101.2% year-over-year — ahead of the 5-year CAGR of +127.4%. This indicates the business is expanding faster than its historical baseline.
What is BBIO's revenue history from 2017 to 2026?
BridgeBio Pharma, Inc. (BBIO) revenue history spans 2017 to 2026. TTM revenue as of 2026 is $692M, growing at +101.2% YoY. The 5-year CAGR is +127.4%. Complete annual and quarterly revenue figures are available on this page, including gross profit, operating income, and margin trends.
What is BBIO's long-term revenue growth rate (CAGR)?
BridgeBio Pharma, Inc.'s 5-year revenue CAGR of +127.4% reflects the sustained nature of its business expansion. As of 2026, the current YoY growth rate of +101.2% is above this long-term average. CAGR is the most reliable measure of sustained revenue momentum for BBIO.
Why does BBIO's quarterly revenue fluctuate?
BBIO quarterly revenue can fluctuate significantly between periods. A quarter-over-quarter (QoQ) change does not always indicate a trend; comparing the same quarter year-over-year (YoY) is a more reliable signal for underlying growth. BridgeBio Pharma, Inc.'s revenue data from 2017 to 2026 shows full historical quarterly detail on this page.
How is BBIO's revenue distributed by segment?
BBIO reports revenue broken down by product line and geographic region. The segment breakdown on this page shows which business units contribute the most to total revenue as of the latest fiscal year. Concentration in a single segment above 50% indicates category dependence, while a diversified mix signals more resilient revenue streams.
How does BBIO's revenue compare to industry peers?
BridgeBio Pharma, Inc. (BBIO) with TTM revenue of $692M and +101.2% YoY growth can be benchmarked against sector peers using the comparison table on this page. Revenue growth relative to peers indicates market share gains or losses. The peer section shows TTM revenue, YoY growth, and operating margin for direct comparisons.